Despite the active state of the PI3K/mTOR pathway, to date, studies of CCI-779 in melanoma have not shown promise [17], [18], indicating that discovery and exploitation of novel survival pathways and mechanisms of resistance would be necessary for further successful development of this agent. Here, MTOR is linked to melanoma.